Articles tagged with Gastrointestinal Neoplasms
Researchers developed new animal models that faithfully reproduce the evolution and malignancy of different human tumors. This allows for parallel tumor progression, prediction of relapses, and assessment of effective treatments in a controlled laboratory setting.
Scientists discovered that bacterial biofilms are associated with colon cancer, particularly in the ascending colon. A novel imaging technique revealed diverse microbial communities in these biofilms, suggesting a possible link between bacteria and tumor development.
Researchers discovered that a genetic modifier called Pla2g2a can protect against colon tumors in mice, which could have significant implications for cancer research and treatment. The study found that mice with the resistant allele of Pla2g2a had fewer tumors than those with the sensitive allele.
A subset of stage III colon cancer patients with CpG island methylator phenotype (CIMP) showed improved overall survival when treated with irinotecan-based therapy. Patients with CIMP-negative tumors experienced significant harm from the addition of irinotecan, resulting in lower overall survival rates.
Researchers have found that an antibody against EphA3 can slow tumour growth and kill cancer cells by disrupting blood vessels and the tumour micro-environment.
Researchers found that dietary capsaicin triggers a reaction that reduces the risk of colorectal tumors in mice. Chronic activation of the TRPV1 receptor by capsaicin also initiates a negative feedback on EGFR, dampening its activity and reducing unwanted growth.
Researchers found that antihistamines can reverse the effects of myeloid derived suppressor cells in mice with tumors and those with allergy symptoms. This suggests a potential link between allergies and cancer prevention.
Researchers found that bioelectrical signals from distant cells can control tumor formation, with a common fatty acid produced by bacteria playing a key role. This discovery opens up possibilities for preventing, detecting, and treating cancer.
Researchers at CNIO developed a new strategy to personalize cancer therapies for advanced patients by analyzing genetic mutations and testing drugs in 'Avatar' mice. The study showed clinical responses in up to 77% of patients, providing a promising approach for personalized medicine.
A new study has identified PLAC8 as a critical protein involved in the spread of colon cancer. Elevated levels of PLAC8 have been linked to abnormal cell behavior, leading to faster tumor growth and increased invasiveness.
A team identified p38 as a dual role in colon cancer, both protecting the epithelial barrier and promoting tumour growth. Treatment with a p38 inhibitor reduced tumour size in mice.
Researchers have discovered a feedback loop between IL-6 and microRNA-34a that promotes tumor cell mobility and metastasis. The loop involves the activation of STAT3, which represses miR-34a production and leads to increased tumor-promoting proteins.
Researchers found that several chemotherapy drugs cause hyper proliferation in stem cells, leading to tumor recurrence. The study used fruit flies as a model, discovering compounds that inhibit tumors without causing this side effect.
A study by Arizona State University researchers links CXCR2 to tumor formation, growth, and progression in colon cancer. The genetic culprit is implicated in recruiting immune cells that evade the immune response, providing a new clue for developing therapeutic targets.
A new study published in mBio found that transferring gut microbes from mice with colon tumors increased the risk of tumors in germ-free mice. The research indicates that inflammation and interactions between gut microbiota play a critical role in tumor formation.
Researchers at LMU identified ZNF281 as a critical factor in colon cancer metastasis, driving the transition from epithelial to mesenchymal cells. The protein's inhibition prevents metastasis in mice, suggesting a potential therapeutic strategy for colon cancer treatment.
Two studies link fusobacteria from mouth to colorectal cancer formation by stimulating bad immune responses and activating cancer growth genes. Fusobacteria rely on FadA molecule to attach to and invade human cells, promoting tumor growth.
Researchers discovered a biological mechanism that preserves intestinal tracts in mice treated with lethal doses of chemotherapy, increasing survival rates by up to 75%. The findings could revolutionize cancer therapy by allowing humans to tolerate stronger doses of chemotherapy and radiation, potentially curing later-stage metastasize...
Removing MerTK from immune cells decreases tumor growth and metastasis in breast, melanoma, and colon cancers. Inhibition of MerTK may stimulate anti-tumor responses and have clinical benefits.
Researchers found that consuming soy peptide lunasin orally reduced the number of metastatic tumors in mice with human colon cancer cells. The highest dose of 20 mg/kg of lunasin achieved a 94% reduction in tumors, showing promise for new cancer treatment approaches.
A multi-institutional registry study involving 450 patients found that PRRT treatment significantly prolonged overall survival, with median progression-free survival of up to 51 months. Patients with pancreatic tumors survived an average of 39 months without disease progression.
Scientists at Nanyang Technological University and Lund University have bioengineered a novel molecule, HAMLET, which has been proven to successfully kill tumour cells. The molecule is based on a natural protein present in human breast milk and has been shown to suppress colon cancer in laboratory mice.
Researchers at Columbia University Medical Center have identified hundreds of metabolic expression changes and potential drug targets to cut off a tumor's fuel supply. The study, published in Nature Biotechnology, provides a comprehensive view of diverse metabolic alterations in cancer, shedding light on how tumors adapt their metaboli...
Researchers have developed a new preclinical technology that enables quick determination of a treatment's effectiveness against gastrointestinal stromal tumors (GISTs) as early as 24 hours after administering the compound. This tool can help identify new drugs or drug combinations and quickly identify the most effective treatments for ...
Researchers found that combining non-steroidal anti-inflammatory drugs with cholesterol-lowering medication Lipitor can effectively prevent colorectal adenomas in mice. In contrast, the same combination was only effective when administered to mice with existing tumors.
A team of researchers at UT Southwestern Medical Center has identified a specific genetic weakness in lung-cancer cells that can be targeted with new therapies. The discovery, published in Cancer Discovery, highlights the potential of blocking the protein RHOA and focal adhesion kinase (FAK) to stop tumor growth.
A mouse study published in Cancer Prevention Research found that removing visceral fat reduces the development of intestinal tumors. The study also showed gender differences in how adiposity affects cancer risk, highlighting the need for targeted strategies to reduce abdominal obesity and promote weight loss.
Scientists have generated molecules that inhibit tumour cell adhesion to other cells, halting both tumour growth and liver metastasis. The breakthrough could lead to new treatments for colon cancer and its related death toll.
Scientists at Max Planck Institute for Molecular Genetics discovered a recurring pattern of over 13,000 epigenetic alterations in young mouse tumours, which is partly conserved in human colon carcinoma. This finding may facilitate the identification of novel clinical colon cancer biomarkers for early detection.
Researchers at Sanford-Burnham Medical Research Institute discovered that tumors lacking the protein PKCζ can survive on alternative nutrients. The study suggests glucose depletion therapies may work against these tumors as long as they produce PKCζ, which is responsible for tumor metabolism.
A team of researchers found that tumour cells form alliances with surrounding healthy cells, called stroma, to colonize other organs during metastasis. This discovery could lead to a test to predict relapse and tailored treatment regimes for patients.
Researchers discovered microbial-dependent mechanisms that fuel cancer growth, exploiting immune cells and disrupting tissue homeostasis. Inhibiting inflammation may reduce cancer risk by up to 45%.
A new treatment protocol that includes accurate CT scan analysis and complex surgical technique has significantly increased long-term survival for patients with previously inoperable pancreatic adenocarcinoma. On average, patients lived about 30 months after tumor removal, nearly three times longer than those who never underwent surgery.
Researchers from Johns Hopkins Medicine found that drug-resistant tumor cell mutations appear in the blood of patients five to seven months after treatment begins. Nearly all tumors already contain these low levels of mutations before therapy starts, making cancers predestined to recur.
Surgeons successfully removed tumors from patients with unresectable abdominal cancers by using synthetic vascular grafts and re-implanting organs. All three patients are alive with no tumor recurrence after 2 to 4 years.
Researchers validated two new staging classification systems for neuroendocrine pancreatic tumors, finding that advancing stage correlates with increasing risk of metastatic relapse after surgery. The study also showed that small, low-grade tumors have exceptionally low metastatic potential.
A new predictive tool has been developed to assess the risk of recurrence in gastrointestinal stromal tumours (GIST) following surgery. The tool provides more accurate prognosis for individual GIST patients compared to conventional models, helping to identify those most likely to benefit from additional treatment.
A team of scientists at Sanford-Burnham Medical Research Institute has developed a new method for delivering cancer drugs directly to tumors, reducing side effects and increasing effectiveness. The technique uses a tumor-homing peptide that targets blood vessels feeding tumors, allowing the drug to be administered with minimal impact o...
Researchers used genetically modified mice with human-like enzymes to assess the health risks of food mutagens from well-done meat and fish. The results showed a significant increase in intestinal tumors after consuming substances from meat crust, highlighting the need for better models to predict human health effects.
A new fourth-generation oncolytic virus has shown greater effectiveness against human brain cancer, improving survival by 50% compared to previous versions. The virus is engineered to replicate in cells expressing nestin, a marker for neuronal stem cells and glioblastoma.
Researchers have identified a mechanism that explains how cancer cells change their appearance and progress from a solid state to a semiliquid mass. The study found that microRNA-200S inactivation leads to this transformation, allowing tumour cells to evade natural defences and invade neighbouring organs.
Researchers will analyze tumor samples from 100 patients with large intestine cancer or chronic lymphatic leukemia before and after drug treatment. The goal is to identify genetic mutations that contribute to treatment resistance, enabling the development of more effective cancer therapies.
A prospective cohort study found that a tumor marker and targeted endoscopic ultrasound can detect stage 1 pancreatic cancer in high-risk populations more effectively than standard means of detection. The study identified a total of one patient with stage 1 disease among 546 enrolled participants.
Researchers found that testing every new colon cancer patient for Lynch syndrome can reduce cancer deaths at a reasonable cost. Testing multiple family members after the initial diagnosis is crucial to spreading the benefit across more relatives, according to the study.
Scientists at Tufts University found that mice born to mothers fed a B vitamin-rich diet had fewer intestinal tumors, while those from deficient diets showed more aggressive tumors. The study suggests epigenetic effects of maternal B vitamin intake may protect against colorectal cancer in offspring.
Researchers develop a new therapy to prime tumors before radiotherapy, reducing damage to healthy tissue. The treatment shows effective targeting of tumors with minimal side effects.
The new nanoparticles can carry hundreds of light-sensitive molecules, creating more reactive oxygen species from the same amount of light. This design allows the nanoparticles to penetrate easily into tumors and deliver targeted damage to cancer cells.
Researchers at Dana-Farber Cancer Institute conducted a phase 1 clinical trial using ipilimumab and bevacizumab to treat advanced, inoperable melanomas. The trial showed that the combination of these two drugs was safe and potentially more effective than either drug alone.
Researchers at Fox Chase Cancer Center found that naproxen and its derivative NO-naproxen reduce tumor formation in mutant mice. The data also suggests that naproxen blocks a key step in colon cancer formation, which could lead to the development of new chemopreventive agents.
Researchers at North Carolina State University have found a compound that induces intestinal birth defects in frog embryos and also inhibits the growth of cancerous tumors. The compound, dubbed 'heterotaxin,' disrupts asymmetry in organ development and prevents normal blood-vessel formation, cell migration, and adhesion.
Researchers Bert Vogelstein and Jan Hoeijmakers received the Brupbacher Prize for their work on the genetic basis of tumor growth, shedding light on colorectal and skin cancers. Their findings have significant implications for understanding lifestyle-related causes of cancer and premature aging.
A new dendritic cell vaccine has been developed at Dartmouth Health, which uses the patient's own tumor cells to stimulate an anti-tumor response. The study found that over 60% of patients who received the vaccine developed immune responses against their tumors, with a significant survival rate five years after treatment.
A University of Illinois Chicago study found that black raspberries can prevent colorectal tumors in two mouse models, reducing tumor incidence by up to 60 percent. The findings suggest that black raspberries' ability to inhibit tumor development may be linked to their suppression of a protein called beta-catenin.
Research by Sergio Lira at Mount Sinai School of Medicine found that HCMV-infected mice develop intestinal tumors as they age, with increased tumor growth compared to normal mice. The study suggests a potential viral link to intestinal cancer in humans, although further work is needed to confirm the association.
A Phase III study showed that everolimus improves progression-free survival by 5.1 months in patients with advanced neuroendocrine tumors. The drug has antitumor efficacy in addition to currently available agents, offering new treatment options for rare cancers.
Research suggests a potential viral link between HCMV and intestinal cancer in mice, where infected cells develop tumors. Meanwhile, scientists identify a key protein regulating breathing in mice and explore survivin as an anticancer target.
A new study published in The Lancet Oncology found that imatinib treatment interruption after 3 years results in rapid relapse and low progression-free survival. Patients who stopped treatment experienced significant tumour growth and poor overall survival, highlighting the need for continuous treatment to maintain cancer control.
A rare case report describes a 68-year-old man with abdominal bloating caused by intussusception due to small intestine lipomatous lesions located in a jejunal duplication cyst. Multiple lipomas within jejunal duplication cysts are rare and difficult to diagnose before surgery, emphasizing the need for appropriate examination methods.
Researcher Dolores Takemoto found a correlation between protein Coonexin46 and hypoxia, leading to potential treatments for retinoblastoma and breast cancer. Her study suggests that siRNA medication could prevent tumor growth by suppressing Cx46.
Researchers found that toxin Paton-Valentine leukocidin does not affect MRSA-induced pneumonia. A novel inhibitor of tumor angiogenesis was discovered in the metalloprotease ADAMTS9. Additionally, Kallikrein-related peptidase 4 (KLK4) may activate protease-activated receptors promoting colon cancer development.